Business Context and Reporting Period
This Form 8-K Current Report was filed by LeMaitre Vascular, Inc. on August 28, 2021. The report details the entry into a material definitive agreement and other events related to the Company's 2019 asset purchase from Admedus Ltd (now Anteris Technologies Ltd).
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed relates to a specific earn-out provision:
- Earn-out Amount: $2 million associated with CE Mark Approvals for the CardioCel and VascuCel biologic patch business.
Material Changes and Agreements
The Company entered into an amendment to its October 11, 2019, Asset Purchase Agreement with Admedus. Key changes include:
- Regulatory Responsibility: LeMaitre Vascular, Inc. will assume responsibility for filing for regulatory approvals (CE Mark Approvals) under the European Union Medical Device Regulation for the acquired Products.
- Cost Allocation: The Company will assume the costs of obtaining these approvals. These costs will be deducted from the $2 million earn-out payable to Admedus.
- Payment Terms: The earn-out remains payable in installments upon receipt of each Product approval, net of the aforementioned costs.
- Transition Services: A separate amendment extends the term of the transition services agreement with Admedus by nine months, through July 11, 2023.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future outlook, or a discussion of general risks. The primary contingency noted is the successful receipt of CE Mark Approvals, which triggers the earn-out payments to Admedus. The filing text does not provide a clear value for the specific costs expected to be deducted from the earn-out.
Investor Verification Checklist
- Verify the status of CE Mark Approval filings for the CardioCel and VascuCel products.
- Monitor the actual costs incurred for regulatory approvals to determine the final net earn-out payment to Admedus.
- Review the full text of Exhibit 2.1 (Amendment No. 1 to Asset Purchase Agreement) for complete legal terms.
- Confirm the operational impact of the extended transition services agreement through July 2023.